



Demanding it All.

Fiscal Year **2012**  
**ANNUAL REPORT**

Funding innovative cancer research for  
**Treatments. Cures. Life.**

**DEMAND CURES TODAY.**<sup>SM</sup>  
THE GATEWAY FOR CANCER RESEARCH

# DEMAND CURES TODAY.<sup>SM</sup>

THE GATEWAY FOR CANCER RESEARCH



## Vision

To shape a world in which a cancer diagnosis is no longer feared.

## Mission

To fund cancer research in new drug investigations, novel combination therapies and complementary and alternative cancer treatments that will help cancer patients feel better, live longer or be cured **TODAY**.

## Table of Contents

Vision and Mission	2
Welcome Letter	3
Measures of Success	4
Patient Story: Michelle Ashby	6
Patient Story: Tiffany Heigle	7
Patient Story: Tom Oberdorf	8
Research: Novel Uses of Existing Drugs	9
Research: Complementary and Alternative Medicine (CAM)	10
Research: New Drug and Treatment Discoveries	11
Funding and Development	13
Cures 2011 Gala	14
Team Demand	15
Fund-A-Day	16
The Cancer Canvas	17
Financial Highlights	18
Board Members and Staff	19

**The Gateway for Cancer Research** is a 501(c)(3) nonprofit organization, and we support truly innovative, Phase I and Phase II clinical trials that have the potential to positively impact the lives of cancer patients. To do so, we provide grants to researchers from world-renowned, cancer research institutions.

\*The individual on the front cover participated in our “Cancer Stories: If I could Talk to You Again” video that was presented at the Cures 2011 Gala.



Dear Friends,

This past year marked an important time of finding and funding bold new research that has translated into promising treatments that can help cancer patients **NOW**.

For example, Dr. Avigan created an adendritic cell vaccine that has proven to amplify the body's immune response to fight myeloma; Dr. Seely used a natural, non-toxic product to improve cancer patient's quality of life; and Dr. Lin's novel method of attacking cancer stem cells to treat late-stage colon cancer has shown very encouraging results.

The Gateway is funding exciting and innovative research in traditional and integrative therapies at renowned research centers including UCLA, Sloan-Kettering, Harvard Medical School, Johns Hopkins and MD Anderson, among many others. We are committed to funding research with the potential to produce unique and innovative cancer treatments that move rapidly from the lab to the bedside to help patients who need them, via Phase I and II clinical trials. With our voices rising, we continue to demand change within a broken system that compels us to stand up and fight, so that patients may live longer, feel better or be cured **TODAY**.

In the pages that follow, we will update you on our efforts to win the war against cancer. We are extremely grateful to the patients who have allowed us to share their courageous stories of hope and life. We are also grateful to you for uniting with us in this cause.

We also extend continued and heartfelt thanks to the Cancer Treatment Centers of America for their generous underwriting, so that **99 cents** of every dollar received can go directly to research and treatments that can help people **NOW**. For cancer patients and their loved ones, there is no time to waste.

Together, we will continue to discover and fund leading edge cancer research that empowers patients, and rewards your continuing support.

Yours in health, hope and wellness,

A handwritten signature in black ink, appearing to read "R. J. Stephenson". The signature is fluid and cursive, with a long horizontal line extending to the right.

Richard J Stephenson  
*Chairman of the Board of Directors, The Gateway For Cancer Research*



Over \$2 Million raised at the Cures 2011 Gala.

Celebrated 20 years of funding research to patients and their families.

Funded 13 patient-centered clinical trials.

Independent fundraisers raised over \$60,000 for The Gateway.

Launched Team Demand, a grassroots fundraising program for active individuals.

Increased Facebook following by 15,000.

Attracted 1,437 new supporters of The Gateway.

Started an online cancer community—Cancer Canvas.

Partnered with chefs nationwide to raise awareness about eating healthier foods to help prevent and fight cancer.

Partnered with Lifetime Network's The Balancing Act.

# It is only and always about the patient.

“ I credit Dr. Lin for the past 10 years of my life. Because of his research and new treatment approach, I have been blessed to see my children grow up, and have this precious time with my entire family. ”

—Tiffany Heigle, cancer survivor and mom, stage 4 colon cancer

“ Cancer continues to strip our communities of mothers, fathers, sisters, brothers and lifelong friends. The Gateway has a full recognition of this injustice and is wholly committed to finding cures. It is refreshing to see an organization set aside bureaucracy to focus on the crisis of cancer. ”

—Michelle Ashby, cancer survivor and mom, stage 4 breast cancer

“ My youngest daughter was nine at the time of my diagnosis. As a stage 4 cancer patient I remember wishing I would live another two years to see her through to age 11, and now she's 14! Thanks to The Gateway, and Dr. Lin's treatment protocol, I am healthy and am hoping for another 50 years. ”

—Tom Oberdorf, cancer survivor and dad, colorectal cancer

## PATIENT STORY : MICHELLE ASHBY



“Participating in a clinical trial gives a renewed sense of hope, and I am so grateful for The Gateway’s perseverance. I feel so fortunate to have participated in this trial; not just for me, but to possibly help find cures that will save the lives of others.”

—Michelle Ashby, cancer survivor and mom, stage 4 breast cancer

Michelle Ashby is a nurse and mother to two young children. On December 23, 2009, she was diagnosed with a rare and aggressive form of inflammatory stage 4 breast cancer. She had no lumps in her breasts, no history of breast cancer in her family and a recent mammogram was normal. The only reason Michelle even

visited her primary care physician was because she had experienced unusual weight loss and had some back pain.

By the time she was diagnosed, Michelle’s cancer had already spread to her pelvis, spine, skull and liver. By Christmas Eve, her pain was so unbearable that she could hardly walk. She was overwhelmed and terrified, imagining this could be the last holiday she would spend with her husband and children.

Michelle received her first radiation treatment and course of chemotherapy at Washington University in St. Louis. She was accepted into a breast cancer vaccine trial being funded by The Gateway and led by Dr. William Gillanders and Dr. Timothy Fleming.

Timothy Fleming, PhD, was part of a team that first identified mammoglobin-A as an effective breast cancer marker. This natural protein is expressed at low levels in normal breast tissue, but is dramatically overexpressed in 80% of primary and metastatic

breast cancers. Dr. Fleming joined the immunology team at Washington University to develop a vaccine to prime the patient’s immune system to attack breast cancer with the right self-antigen: mammoglobin-A.

The custom vaccine was constructed from DNA segments that encode mammoglobin-A in order to trigger T cells to recognize the protein as a foreign body on the surface of tumor cells. The vaccine is designed to be especially good at destroying hidden cells not detected by traditional radiation or chemotherapy.

Michelle continued traditional treatments while also receiving three vaccines. She and her family are overjoyed to report she has been cancer-free for just over two years. The results of Dr. Gillanders’ study have been extremely promising—he is in the process of preparing for a large-scale clinical trial to attempt to achieve the same results on a larger scale.

As a mother of two small children, Tiffany Heigle was devastated to hear she had cancer. At the young age of 33, Tiffany was faced with the challenge of battling stage 4 colon cancer. With no family history of colon cancer and a young family to care for, Tiffany was nervous about the journey ahead.

The first step in Tiffany's cancer journey was surgery. She had 10 to 12 inches of her colon removed, as well as numerous lymph nodes that tested positive for cancer. Under the care of her oncologist, Dr. Brian Geister, Tiffany underwent six months of chemotherapy.

This was just the beginning of Tiffany's cancer journey. What followed for Tiffany and her family would be two more rounds of surgery and chemotherapy. Yet, the cancer continued to re-appear in Tiffany's lymph nodes. After three surgeries and multiple courses of chemotherapy and radiation, Tiffany's oncologist made a life-saving decision for Tiffany.

Dr. Geister referred Tiffany to Dr. Edward Lin at MD Anderson Cancer Center in Houston, Texas. Dr. Lin, who was one of the first oncologists to specifically target colon cancer stem cells, was investigating a new therapy that could help patients just like Tiffany.

After consulting with Dr. Lin, Tiffany was enrolled in a clinical trial. Dr. Lin's study, a Phase II ADAPT Therapy, was a unique treatment regime involving a novel combination of chemotherapy, radiation and celecoxib, an FDA- approved arthritis drug.

The results were promising. For three and a half years, which included 23 sessions of radiation paired with chemotherapy and celecoxib, Tiffany's scans were clear. No cancer. Although Tiffany needed another round of chemotherapy to address a swollen lymph node and inflamed kidney, she returned to the study's treatment regime soon thereafter. Today, Tiffany is doing well, her scans remain clear and she appears to be in full remission.

Throughout Tiffany's enrollment in the clinical trial, both Drs. Geister and Lin worked closely together, discussing treatment plans, exchanging test results, and sharing updates on Tiffany's health and progress.

As a result of Dr. Lin's clinical trial and his innovative approach for treating colon cancer, Tiffany has been a part of her children's lives, spending valuable time together and watching them become young adults. She now has an 19 year-old freshman in college and a 16 year-old freshman in high school.



“I credit Dr. Lin for the past 10 years of my life. Because of his research and new treatment approach, I have been blessed to see my children grow up, and have this precious time with my entire family.”

— Tiffany Heigle, cancer survivor and mom, stage 4 colon cancer

## PATIENT STORY : TOM OBERDORF

When Thomas Oberdorf, father of four, moved with his family to Seattle for his new job, nothing could have prepared him for how fate had landed him exactly where he needed to be for the journey ahead. Plagued by stomach troubles, Tom underwent a colonoscopy. He learned he had cancer upon awakening from the anesthesia. Tom will never forget his shock in receiving the news.

Tom's cancer had already metastasized to his liver. He met with Dr. Edward Lin, an accomplished researcher and expert in gastrointestinal cancers, who had also just moved to Seattle from MD Anderson in Texas to join the Seattle Cancer Care Alliance.

Dr. Lin informed Tom that he had stage 4 colorectal cancer, with a five percent chance of surviving for five years. Lin also said that they would "throw everything at it," and began Tom's treatment. What followed was three months of intensive chemotherapy, six weeks of radiation, and then colon and liver operations in October and December. With each surgery, Tom was back to work within days. His goal was to keep going, no matter what.

Following his second surgery, Tom continued treatment for another two years on a unique combination drug therapy created by Dr. Lin. The treatment protocol, called ADAPT Therapy, activates cancer stem cells that traditionally hibernate during chemotherapy—a main cause of treatment failure—so the cancer stem cells can be destroyed.

After two years on Dr. Lin's protocol, Tom had a clean CT scan. At 54, Tom is five years cancer-free. He is healthy and able to enjoy his life and time with his family.



“My youngest daughter was nine at the time of my diagnosis. As a stage 4 cancer patient I remember wishing I would live another two years to see her through to age 11, and now she’s 14! Thanks to The Gateway, and Dr. Lin’s treatment protocol, I am healthy and am hoping for another 50 years.”

—Tom Oberdorf, survivor and dad, colorectal cancer

# RESEARCH Highlights

WE BELIEVE SUCCESS IS MEASURED WHEN PATIENTS ARE HEALED, QUALITY OF LIFE IS RESTORED AND MORE TIME CAN BE SPENT WITH LOVED ONES.

We are proud to seek out medical researchers devoted to finding breakthroughs in all areas of cancer research for all types of cancer. During FY 2012, Gateway funded studies focused on sarcoma, leukemia, myeloma, brain, colorectal, lung, blood, cervical, prostate, breast and skin cancers.


Believing patients' best option to fight cancer is through an integrated oncology model, Gateway funds Phase I and Phase II clinical trials and strives for a balanced research portfolio consisting of 40% novel use/combination of existing drugs, 40% complementary and alternative therapies and 20% new therapy/drug discoveries.

## NOVEL USE OF EXISTING DRUGS

It normally takes about one billion dollars and 10 years to develop a new drug—an unacceptable timeline for people who need help **TODAY**. Dr. Lin's treatment course targets and destroys colorectal cancer stem cells by combining chemotherapy with celecoxib, an FDA approved arthritis medicine. Celecoxib has been available for years, it is potentially faster and cost-effective to make this new combination therapy available to other colon cancer patients who may not have ten months, much less ten years.

### FY 2012 GATEWAY-FUNDED RESEARCH IN THE NOVEL USE OF EXISTING DRUGS INCLUDED:

- DNA vaccines to combat **breast cancer**
- A study aimed to stop tumor cell production in **lung cancer** by decreasing estrogen receptor activation
- Dr. Lin's ADAPT Therapy for **Colon Cancer**



## RESEARCH PORTFOLIO

- Novel Use of Existing Drugs
- CAM Therapies
- New Drug and Treatment Discoveries

## CAM Therapies

CAM stands for Complementary and Alternative Medicine. It is a term used to describe a wide range of healing systems that are not considered part of mainstream or conventional Western medicine, such as natural products, mind-body medicine and manipulative and body-based practices. It is rarely, if ever, funded by mainstream organizations because there is little or no profit in the use of existing natural remedies. It is particularly important to fund CAM research because it can offer patients potentially non-toxic therapies to battle cancer, improve quality of life and maximize the effectiveness of chemotherapy and radiation therapies.

### **FY 2012 GATEWAY-FUNDED CAM THERAPY CLINICAL TRIALS INCLUDED:**

- The use of water-soluble curcumin, a spice derivative of turmeric, in tumor reduction.
- The efficacy of melatonin in treating lung cancer.
- The promising effect of stress reduction in combination with beta blockers to reduce the impact of neuroadrenaline on cervical cancer.
- The use of a non-invasive, Chinese herbal cream in fighting anal cancer.
- Investigating the efficacy of green tea polyphenols and active surveillance in treating and delaying the progression of low-risk prostate cancer.
- Antibody therapy for treating rarely curable chronic Lymphocytic Leukemia that tests if combining baker's yeast cell wall with the traditional approach will augment the ability of the treatment to kill tumor cells.

# New Drug and Treatment Discoveries

WE NEVER WAIT FOR THE RESEARCH TO FIND US—WE FIND THE RESEARCH.

New drug and treatment discoveries are just that—the process of developing a therapeutically active substance for a defined target molecule or pathway. This type of research is very costly, takes a long time, faces many rigorous and onerous FDA approvals and the success rate is extremely low. Since new cancer therapies are desperately needed, we chose to fund only the most promising research in this category that have the potential to change the way cancer is treated, **NOW!**

**IN FY 2012, WE ACTIVELY SOUGHT OUT AND FUNDED NEW DRUG AND NOVEL TREATMENT APPROACHES THAT HAVE THE POTENTIAL TO HELP CANCER PATIENTS TODAY! THESE INCLUDE:**

- A novel immunotherapy with donor tumor-specific T-cells for patients with difficult-to-treat blood cancers, such as myeloma.
- Immunotoxin therapy using a new agent molecule that seeks and selectively destroys tumor cells in various cancers with significantly reduced injury to normal tissues as compared to chemotherapy.
- Personalized medicine for patients with metastatic melanoma, using over 20 novel agents and genomic profiling.
- A novel vaccine including ten different peptides that increase the probability to elicit an immune response to attack cancer cells in glioblastoma. Other vaccines have single or triple peptides at the most.
- A multi-drug combination that inhibits tumor growth in patients with metastatic sarcoma.

For a full list of clinical trials and researchers funded by The Gateway, please visit [demandcuretoday.org](http://demandcuretoday.org).

TODAY

The Gateway is a patient-centered, single mission organization devoted to funding innovative cancer research that can improve patients' lives TODAY. Thanks to generous underwriting by Cancer Treatment Centers of America, 99 cents of every dollar received goes directly to fund research. We are proud to fund researchers

who focus on speeding results to patients who need them **NOW**.

Accountability to donors and cancer patients everywhere is the cornerstone of our research funding model. We directly

## Accountability to Cancer Patients...and Their Loved Ones

oversee every research grant to ensure that we understand the progress, and where and how donations are being spent. We withhold some of the grant money until the research is final, ensuring that we know the full outcome of the trials you have helped us fund.

The Gateway uses a pay-per-patient model. Unlike most foundations, we do not provide lump sum payment in advance. Instead, payment to the researcher is triggered whenever a new patient is enrolled and treated in the clinical trial.

These aspects of our funding model incentivize our research teams to move more quickly instead of slowing the research process, and potentially needing more funding. We truly care about patients and the long-term effects of all cancer treatments we fund and we follow up with each study by requiring quarterly progress reports.



NOW

“We are humbled by the generosity of our donors”


—Karen Kay, Director of Development for the Gateway for Cancer Research

## So Many Ways to Make a Difference

SINCE 1991, YOUR DONATIONS HAVE HELPED THE GATEWAY IN FUNDING \$20 MILLION IN LEADING-EDGE CANCER RESEARCH.

### HOW MUCH YOU RAISED

Thanks to you, we raised more than **\$2.6 million nationwide**, exceeding donations last year by **27.8%**. It is an impressive amount that reflects the compassion, generosity and unwavering commitment to putting cancer patients first. Together, we continue to help save and improve lives **NOW**, not decades from now.



# Treatments. Cures. Life.

DEMANDING IT ALL.

## SPONSORS

- AmerisourceBergen
- Bank of America
- Cancer Treatment Centers of America
- CTCA at Eastern Regional Medical Center
- CTCA at Midwestern Regional Medical Center
- CTCA at Southwestern Regional Medical Center
- CTCA at Western Regional Medical Center
- CTCA at Southeastern Regional Medical Center
- Dick and Carolyn Riley
- Insight
- International Capital & Management Company
- Katten Muchin Rosenman LLP
- LarsonAllen LLP
- Merrill Lynch
- N-Jet (Northern Illinois Flight Center)
- Numerof & Associates, Inc.
- PNC Bank
- RCP Advisors LLC
- Rising Tide Foundation
- Stellar Insurance Company Ltd.
- Sunquest Information Systems
- TEAM Companies
- The Bonner Family
- The Templer Family



## Cures 2011 Gala

In a recent review of top Chicago area galas by Crain's Chicago Business, The Gateway was found to be number one in keeping costs down and net proceeds up. The Cures 2011 gala, held at the Fairmont Chicago Millennium Park, was attended by more than 800 guests, uniting patients and supporters.

Gala attendees helped raise more than \$2 million, an impressive 18% increase in funds over the prior year's total.

"We are humbled by the generosity of our donors," Karen Kay said. "The evening was spectacular. We celebrated advances in cancer research and showcased a menu with foods that help to both prevent and fight cancer. We brought together hundreds of people with the shared goal of raising money to fund the right kind of cancer research and save lives now. In this economy, the fact that corporations and individual donors reached deep into their pockets to help us raise more than \$2 million for cancer research speaks to their commitment to vital importance of our work." she said.



# DEMAND

## Team Demand

This past year marked the launch of Team Demand, a mission driven fundraising program uniting cause and community in walks, outings, runs, golf tournaments, concerts and a mudathalon. This is a significant initiative that will rally communities in grassroots, Gateway-themed efforts. “Team Demand was created as an enjoyable way for people who want to make a difference in the fight against cancer, to get involved and come together to support each other as they unite in our mission to save lives,” says Rhonda Kokot.

The first race for Team Demand, which included about 40 runners, was the Chicago Half Marathon. FY 2012 events also included the Schaumburg Spring Half Marathon and Marathon, Twilight Shuffle 5k, Hollywood Half, and the Route 66 Half Marathon.

For Gateway board member and ten-year cancer survivor Rhonda Kokot, *“Being part of Team Demand is about more than raising money. Participating in events like 5Ks and half marathons are a great way to get healthy and build community.”*

Kokot, who needed a bone marrow transplant to survive, celebrated her decade-long victory over leukemia by pushing herself to raise \$10,000 this year for The Gateway, an effort she calls the “10-10-10 Challenge”—10 years as a cancer survivor, \$10,000 for cancer research and 10 races in one year. For progress on Rhonda’s goal, visit [demandcurestoday.org/Rhonda](http://demandcurestoday.org/Rhonda).

**For more information on Team Demand visit:**  
[DemandCuresToday.org/TeamDemand](http://DemandCuresToday.org/TeamDemand)



# FUND-A-DAY

## Fund-A-Day



For cancer patients and survivors each day is precious, but some days are more memorable than others. Days bringing news like clean scans, remission or being well enough to leave the hospital have particular meaning. There are also the days that someone loses their battle.

The new Fund-A-Day Calendar helps individuals or families commemorate all these important days with inspiring messages, while helping to fund cancer research. In FY 2012, it costs an average of \$28.16 to fund one day of one clinical trial for one patient in a Gateway-funded study.



“Reading the touching messages on the Fund-a-Day web page can be heart wrenching; many are memorials to loved ones who lost the battle,” says Karen Kay. “Funding a day for a patient in a clinical trial, those remaining are helping to reduce the number of lives lost to cancer. We can’t think of a better tribute. We hope it brings some peace and solace to know a life may be saved, while letting the world know about a special person who has cancer or has died from it.”

For more information on Cancer Canvas visit:  
[demandcurestoday.org/fund-a-day-calendar](http://demandcurestoday.org/fund-a-day-calendar)

# Heart and Soul: The Cancer Canvas

We know that treating and curing any disease is not just about treating the body—it is also about treating the mind and spirit. In FY 2012, we launched the Cancer Canvas, a poignant, visual montage featured on our website that gives a voice to the challenges faced by cancer patients, survivors, and their loved ones.

The Cancer Canvas helps individuals come together to find support and comfort in personalized messages of courage, hope and perseverance. Visitors provide personal messages and upload a photo or use an inspirational image from The Gateway. From the date of its launch, the cancer canvas has grown to over 1,200 messages. Every single day, the number of messages on the cancer canvas increases, showing that more people are passionately calling for cures.



For more information on Cancer Canvas visit:  
[demandcurestoday.org/cancercanvas](http://demandcurestoday.org/cancercanvas)

## FINANCIAL HIGHLIGHTS

# FINANCIAL HIGHLIGHTS

## Year Ended June 30, 2012

### FUNDRAISING REVENUE

Contributions	\$615,938
Special events	\$2,081,224

### RESEARCH GRANTS

Awarded Grant Funds	\$1,981,500
---------------------	-------------

### ASSETS

Cash and cash equivalents	\$2,846,432
Pledges and other receivables	\$259,602
Prepaid expenses	\$2,539
Certificates of Deposit	\$3,973,554
Interests in limited partnerships	\$8,350

**Total Assets** \$7,090,477

### LIABILITIES AND NET ASSETS

Accrued grants	\$2,535,404
Net Assets	\$4,555,073

**Total Net Assets and Liabilities** \$7,090,477

\*Thanks to generous underwriting by Cancer Treatment Centers of America for Gateway's administrative expenses, which includes employee compensation, 99% of all contributions received directly fund researchers who are conducting Phase I and Phase II cancer clinical trials.

\*Form 990 available upon request.

## BOARD MEMBERS AND STAFF

### BOARD OF DIRECTORS

#### Chairman

Richard J Stephenson  
*Cancer Treatment Centers  
of America*

#### Vice Chairman

Bruce Lubin  
*The Private Bank & Trust Co.*

#### Vice President

Dottie Rzeszutko  
*CA Fortune*

#### Treasurer

Michael T. Mullins  
*Winston & Strawn, LLP*

#### Secretary

Rod Murray  
*Associated Bank*

#### Directors

Michael Clune  
*Clune Construction Co.*

Wayne Dixon  
*H.S. Crocker Co., Inc.*

Tom Duensing  
*Thomas R. Duensing  
and Assoc.*

Susan Fleming  
*Catamaran*

Joseph Gregoire  
*PNC Bank*

Rhonda Kokot  
*Simple Truth*

Robert Mayo

*Cancer Treatment  
Centers of America*

Edwin Roberson  
*Raphael Biotech, Inc.*

Mary Lou Smith  
*Research Advocacy  
Network*

Harlan Teller  
*FTI Consulting*

### BOARD OF SCIENTIFIC COUNSELORS

David Berd, MD  
*Medical Oncology consultant*

Nelson Chao, MD, MBA  
*Duke University Medical Center*

Robert Fine, MD  
*Columbia University*

Timothy Fleming, PhD  
*Washington Univ. School of  
Medicine*

Judy Fulop, ND, FABNO  
*Northwestern Integrative  
Medicine*

Kay Kays  
*Patient Research Advocate*

David Lacewell  
*Patient Research Advocate*

Jeannine McCune, PharmD  
*Univ. of Washington Medical  
Center*

Ronald Morton, MD  
*Endo Health Solutions*

Joseph Pizzorno, ND  
*Bastyr University*

Takami Sato, MD, PhD  
*Jefferson University*

### GATEWAY STAFF MEMBERS

Pamela Barrett  
*Manager of Development*

Carol Christian  
*e-Marketing Manager*

Wendy Lynn Duffer  
*Marketing Specialist*

Jeremy Garber  
*Development Specialist*

Kathy Gehrig  
*Assistant*

Karen Kay  
*Director of Development*

Ashlee Landis  
*Marketing Specialist*

Eveline Mumenthaler  
*Director of Research and  
Grants*

Keshia Osley  
*Research Specialist*

Jennifer Seppi  
*Development Specialist*

Adam Zuckerman  
*Marketing Manager*

## IN MEMORIAM



**Ken Smith** passed away peacefully in July 2012, surrounded by his loving family and friends after a long battle with cancer. Ken was a devoted husband, father, grandfather, son and friend to all who were blessed to be touched by his effervescent personality, quick sense of humor and adventurous spirit.

For the last eight years, Ken was a devoted fundraiser and board member at The Gateway for Cancer Research, serving as the board's Vice Chairman for the last several years, as well as a member of the Executive Committee. Together with his loving wife Maryl, Ken raised over \$650,000 for cancer research, specifically to fund clinical trials to help cancer patients feel better, live longer, and in many cases, succeed in their fight against cancer.

Ken was an "all-in" kind of man. He liked to take the time to focus on what was important, and then pursue it with all of his being. Supporting cancer research, years before he had it, was one of those passions.

The greatest tribute to Ken is that in his short lifetime Ken made a difference. He made a difference in cancer research and in the lives of an untold number of cancer patients. On behalf of every cancer patient and survivor and all of your friends at The Gateway, thank you Ken for being a man of action and not just words.

*\*Listings current as of February 1, 2013*



# 99¢

of every dollar received funds  
cancer research

There are many ways you can join us to Demand Cures Today so more cancer patients can be survivors. Join the conversation on Facebook and Twitter, submit a story to the Cancer Canvas, or Fund-A-Day in honor of a loved one or friend.

Visit [DemandCuresToday.org](http://DemandCuresToday.org)



Local, state and federal employees donate through payroll deductions to The Gateway. A convenient way to give, thousands of civil servants help The Gateway to fund the search for a cure for all types of cancer.

CFC 11719

**DEMAND CURES TODAY.**<sup>SM</sup>  
THE GATEWAY FOR CANCER RESEARCH

1336 Basswood Rd. • Schaumburg, IL 60173 • (847) 342-7450